We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+27.45%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$855M
AUM Growth
-$72.2M
Cap. Flow
-$92K
Cap. Flow %
-0.01%
Top 10 Hldgs %
52.05%
Holding
72
New
17
Increased
11
Reduced
9
Closed
25

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$34.2M
2
INSM icon
Insmed
INSM
+$32.4M
3
CYTK icon
Cytokinetics
CYTK
+$26M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$25.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.7M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$42.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$30.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$30M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23M
5
IMVT icon
Immunovant
IMVT
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
51
Bicycle Therapeutics
BCYC
$275M
– –
-500,000
Closed -$11.3M
BEAM icon
52
Beam Therapeutics
BEAM
$2.7B
– –
-500,000
Closed -$12.3M
CLDX icon
53
Celldex Therapeutics
CLDX
$2.79B
– –
-900,000
Closed -$30.6M
CMPS
54
Compass Pathways
CMPS
$1.46B
– –
-1,159,030
Closed -$7.3M
COGT icon
55
Cogent Biosciences
COGT
$6.95B
– –
-2,000,000
Closed -$21.6M
HELP
56
Cybin Inc
HELP
$471M
– –
-600,000
Closed -$5.33M
ENGN icon
57
enGene Therapeutics
ENGN
$118M
– –
-800,000
Closed -$5.28M
FULC icon
58
CALL
Fulcrum Therapeutics
FULC
$248M
– –
-1,500,000
Closed -$5.36M
LKFT
59
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
– –
-800,000
Closed -$23M
IOBT
60
DELISTED
IO Biotech
IOBT
– –
-493,827
Closed -$519K
IONS icon
61
Ionis Pharmaceuticals
IONS
$9.14B
– –
-750,000
Closed -$30M
LCTX icon
62
Lineage Cell Therapeutics
LCTX
$267M
– –
-5,000,000
Closed -$4.53M
NMRA icon
63
Neumora Therapeutics
NMRA
$311M
– –
-100,000
Closed -$1.32M
NUVL
64
DELISTED
Nuvalent
NUVL
– –
-75,000
Closed -$7.67M
NXTC icon
65
NextCure
NXTC
$22.1M
– –
-208,333
Closed -$3.42M
RCKT icon
66
Rocket Pharmaceuticals
RCKT
$343M
– –
-325,000
Closed -$6M
SLN
67
Silence Therapeutics
SLN
$546M
– –
-200,000
Closed -$3.64M
SRPT icon
68
Sarepta Therapeutics
SRPT
$1.63B
– –
-150,000
Closed -$18.7M
BOLD
69
Boundless Bio
BOLD
$55.5M
– –
-58,903
Closed -$204K
SKYE icon
70
Skye Bioscience
SKYE
$21.6M
– –
-100,000
Closed -$391K
ORKA
71
Oruka Therapeutics
ORKA
$5.46B
– –
-257,330
Closed -$6.31M
BCAX
72
Bicara Therapeutics
BCAX
$1.77B
– –
-800,000
Closed -$20.4M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2024 Portfolio in Review

As of Q4 2024, Logos Global Management held 72 positions worth $855M, down 7.8% from $927M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management's Q4 2024 filing shows 17 new, 11 increased, 9 reduced and 25 closed positions. Its largest new stake was BioNTech: 300,000 shares worth $34.2M. The largest sale was Disc Medicine, an estimated $42.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

  • Logos Global Management's largest Q4 2024 buy was BioNTech: 300,000 shares worth $34.2M.
  • Logos Global Management added most to Cytokinetics in Q4 2024, an estimated $26M increase.
  • Logos Global Management's biggest Q4 2024 reduction was Disc Medicine, cutting an estimated $42.5M.
  • Logos Global Management fully exited Celldex Therapeutics in Q4 2024, selling an estimated $30.6M.
  • Logos Global Management's ten largest holdings make up 52% of its $855M portfolio in Q4 2024.
  • Logos Global Management opened 17 new positions and closed 25 in Q4 2024.
  • Logos Global Management's portfolio value fell 7.8% quarter-over-quarter to $855M.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.